Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$43.50 USD
+0.81 (1.90%)
Updated May 29, 2024 04:00 PM ET
After-Market: $43.48 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Corbus Pharmaceuticals Holdings, Inc. [CRBP]
Reports for Purchase
Showing records 21 - 40 ( 60 total )
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Along With DM Top-line Expected 2Q21, Steps to Broaden CB Agonist Reach
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Along With Protocol Amendment in DM, Pipeline Reboot Presents Potential Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Phase 2b Miss in CF Presents Next Steps Forward for the DM Platform; PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Topline Disappointment in Phase 3 RESOLVE-1 Trial, Focus Shifted to CF and DM Advancement; PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Immunosuppressants Obliterate Lenabasum''s Chance to Win
Provider: Roth Capital Partners, Inc.
Analyst: PIERCE E
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Lenabasum Platform Primed for Clarity, Anticipated SSc and CF Topline Data Expected 3Q20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
Resolved an Overhang - Cash Is No Longer an Issue
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Corbus Pharmaceuticals Holdings, Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and 12-month target price of $40/share
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E